Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)

Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 6.53% compared to -4.74% for the MSCI USA Small-Cap Value Index (the “Index”) and 4.96% return for the Russell 2000 Value Index. For more information on the fund’s top picks in 2025, please check its top five holdings.

In its second-quarter 2025 investor letter, Third Avenue Small-Cap Value Fund highlighted stocks such as Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company. The one-month return of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was 21.41%, and its shares gained 27.29% of their value over the last 52 weeks. On August 8, 2025, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stock closed at $41.23 per share, with a market capitalization of $2.312 billion.

Third Avenue Small-Cap Value Fund stated the following regarding Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its second quarter 2025 investor letter:

“Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced an opportunistic acquisition of Sage Therapeutics, which will be funded by Supernus’ $460 million net cash balance. Sage is a company which makes the first and only F.D.A. approved treatment for postpartum depression and, itself, possesses net cash in excess of $420 million as of its most recent filing.”

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

A lab technician analyzing a sample in a laboratory, showing the rigorous research conducted by the biopharmaceutical company.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 26 hedge fund portfolios held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) at the end of the first quarter, which was 27 in the previous quarter. While we acknowledge the risk and potential of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and shared the list of best pharma stocks to buy for long term growth. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.